Fujimura Taku, Kambayashi Yumi, Ohuchi Kentaro, Amagai Ryo, Sato Yota, Tanita Kayo, Hashimoto Akira, Aiba Setsuya
Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Case Rep Oncol. 2020 Mar 24;13(1):271-275. doi: 10.1159/000506327. eCollection 2020 Jan-Apr.
Since the incidence of mucosal melanoma is higher in the Japanese population compared to Caucasians, and since mucosal melanoma possesses a lower mutation burden compared to cutaneous melanoma, the efficacy of anti-PD1 antibody (Ab) monotherapy for mucosal melanoma is limited. Therefore, other targeting molecules that enhance the anti-tumor effects of immune checkpoint inhibitors are needed. In this report, we present a case with anti-PD1 Ab-resistant recurrent malignant melanoma of the nasal cavity successfully treated with nivolu-mab, ipilimumab plus denosumab combination therapy.
由于与白种人相比，黏膜黑色素瘤在日本人群中的发病率更高，且与皮肤黑色素瘤相比，黏膜黑色素瘤的突变负担更低，因此抗PD1抗体（Ab）单药治疗黏膜黑色素瘤的疗效有限。因此，需要其他增强免疫检查点抑制剂抗肿瘤作用的靶向分子。在本报告中，我们介绍了一例鼻腔抗PD1 Ab耐药复发性恶性黑色素瘤患者，该患者接受纳武单抗、伊匹单抗加地诺单抗联合治疗后成功治愈。
